| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Biological Sciences (I.M.B., L.F., M.P.R.T., J.W.), University of Notre Dame, Notre Dame, Indiana 46556; and Departments of Zoology (I.M.B.), and Botany (L.F.), University College Dublin, Belfield, Ireland
Address all correspondence and requests for reprints to: Dr. JoEllen Welsh, Department of Biology, University of Notre Dame, Notre Dame, Indiana 46556. E-mail: jwelsh3{at}nd.edu
To gain insight into the molecular regulation of the human vitamin D3 receptor (hVDR), we have cloned and sequenced the 5' flanking region of exon 1c and examined promoter activity of this region in breast cancer cells. Sequence analysis of the first 1300 bp upstream of exon 1c reveals several characteristics of a class II promoter, including GC-rich regions and the presence of a TATA box at -29 bp. Putative transcription factor binding sites identified in this potential hVDR promoter include AP-2, Sp-1, and glucocorticoid response elements. No consensus vitamin D3 (VDRE) or estrogen (ERE) responsive elements were identified in the promoter sequence. Primer extension analysis performed with a primer specific for exon 1c confirms that transcription initiated in the 5' flanking region of exon 1c occurs in MCF-7 cells. Transient transfection of MCF-7 cells with this putative promoter region cloned into the pRLnull luciferase reporter vector generates significant reporter gene activity that is enhanced by treatment with forskolin, retinoic acid, and 17ß-estradiol. The enhancement of exon 1c promoter activity by 17ß-estradiol is blocked by the selective estrogen response modifier (SERM) tamoxifen and is not observed in estrogen receptor-negative breast cancer cells. In summary, we have cloned and characterized a TATA containing promoter upstream of exon 1c of the hVDR and provide evidence that this region represents a hormonally regulated hVDR promoter.
This article has been cited by other articles:
![]() |
F. Wu, R. Xu, K. Kim, J. Martin, and S. Safe In Vivo Profiling of Estrogen Receptor/Specificity Protein-Dependent Transactivation Endocrinology, November 1, 2008; 149(11): 5696 - 5705. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khan, F. Wu, S. Liu, Q. Wu, and S. Safe Role of specificity protein transcription factors in estrogen-induced gene expression in MCF-7 breast cancer cells J. Mol. Endocrinol., October 1, 2007; 39(4): 289 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seoane, I. Ben, V. Centeno, and R. Perez-Fernandez Cellular Expression Levels of the Vitamin D Receptor Are Critical to Its Transcriptional Regulation by the Pituitary Transcription Factor Pit-1 Mol. Endocrinol., July 1, 2007; 21(7): 1513 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Gilad, O. Tirosh, and B. Schwartz Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells. J. Endocrinol., November 1, 2006; 191(2): 387 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Zella, S. Kim, N. K. Shevde, and J. W. Pike Enhancers Located within Two Introns of the Vitamin D Receptor Gene Mediate Transcriptional Autoregulation by 1,25-Dihydroxyvitamin D3 Mol. Endocrinol., June 1, 2006; 20(6): 1231 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Gilad, T. Bresler, J. Gnainsky, P. Smirnoff, and B. Schwartz Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells J. Endocrinol., June 1, 2005; 185(3): 577 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Schneider, C. El-Yazidi, A. Dace, M. Maraninchi, R. Planells, A. Margotat, and J. Torresani Expression of the 1,25-(OH)2 vitamin D3 receptor gene during the differentiation of mouse Ob17 preadipocytes and cross talk with the thyroid hormone receptor signalling pathway J. Mol. Endocrinol., February 1, 2005; 34(1): 221 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Healy, J. B. Zella, J. M. Prahl, and H. F. DeLuca Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium PNAS, August 19, 2003; 100(17): 9733 - 9737. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Palomba, F. G. Numis, G. Mossetti, D. Rendina, P. Vuotto, T. Russo, F. Zullo, C. Nappi, and V. Nunziata Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes Hum. Reprod., January 1, 2003; 18(1): 192 - 198. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |